Thursday, November 30, 2023 |
Mostly Cloudy

Emergent BioSolutions reaches deal to offload travel vaccines to Bavarian Nordic for up to $380M

February 16, 2023

Gaithersburg biotech Emergent BioSolutions Inc. (NYSE: EBS) said Wednesday it has reached an agreement to sell its travel health business to Denmark’s Bavarian Nordic in a deal that could reach as much as $380 million with milestone payments. The sale agreement comes a little more than a month after Emergent initiated an “organizational restructuring plan” to focus on its drugs and vaccines that protect against public health threats, along with its contract development and manufacturing services.

Article Source: Baltimore Business Journal

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.